Engineering of self-assembled nanoparticle platform for precisely controlled combination drug therapy

Nagesh Kolishetti, Shanta Dhar, Pedro M. Valencia, Lucy Q. Lin, Rohit Karnik, Stephen J. Lippard, Robert Langer, Omid C. Farokhzad

Research output: Contribution to journalArticle

413 Citations (Scopus)

Abstract

The genomic revolution has identified therapeutic targets for a plethora of diseases, creating a need to develop robust technologies for combination drug therapy. In the present work, wedescribe a self-assembled polymeric nanoparticle (NP) platform to target and control precisely the codelivery of drugs with varying physicochemical properties to cancer cells. As proof of concept, we code-livered cisplatin and docetaxel (Dtxl) to prostate cancer cells with synergistic cytotoxicity. A polylactide (PLA) derivative with pendant hydroxyl groups was prepared and conjugated to a platinum(IV) [Pt(IV)] prodrug, c,t,c-[Pt(NH3)2(O2CCH2CH 2COOH)(OH)Cl2] [PLA-Pt(IV)]. A blend of PLA-Pt(IV) functionalized polymer and carboxyl-terminated poly(D,L-lactic-co-glycolic acid)-block-poly(ethylene glycol) copolymer in the presence or absence of Dtxl, was converted, in microfluidic channels, to NPs with a diameter of ∼100 nm. This process resulted in excellent encapsulation efficiency (EE) and high loading of both hydrophilic platinum prodrug and hydrophobic Dtxl with reproducible EEs and loadings. The surface of the NPs was derivatized with the A10 aptamer, which binds to the prostate-specific membrane antigen (PSMA) on prostate cancer cells. These NPs undergo controlled release of both drugs over a period of 48-72 h. Targeted NPs were internalized by the PSMA-expressing LNCaP cells via endocytosis, and formation of cisplatin 1,2-d(GpG) intrastrand cross-links on nuclear DNA was verified. In vitro toxicities demonstrated superiority of the targeted dual-drug combination NPs over NPs with single drug or nontargeted NPs. This work reveals the potential of a single, programmable nanoparticle to blend and deliver a combination of drugs for cancer treatment.

Original languageEnglish (US)
Pages (from-to)17939-17944
Number of pages6
JournalProceedings of the National Academy of Sciences of the United States of America
Volume107
Issue number42
DOIs
StatePublished - Oct 19 2010
Externally publishedYes

Fingerprint

docetaxel
Combination Drug Therapy
Platinum
Nanoparticles
Prodrugs
Drug Combinations
Cisplatin
Prostatic Neoplasms
Microfluidics
antineoplaston A10
Endocytosis
Pharmaceutical Preparations
Hydroxyl Radical
Neoplasms
Polymers
Technology
DNA
poly(lactide)

Keywords

  • Chemotherapy
  • Drug delivery
  • Polymer-drug conjugate
  • Targeting
  • Temporal release

ASJC Scopus subject areas

  • General

Cite this

Engineering of self-assembled nanoparticle platform for precisely controlled combination drug therapy. / Kolishetti, Nagesh; Dhar, Shanta; Valencia, Pedro M.; Lin, Lucy Q.; Karnik, Rohit; Lippard, Stephen J.; Langer, Robert; Farokhzad, Omid C.

In: Proceedings of the National Academy of Sciences of the United States of America, Vol. 107, No. 42, 19.10.2010, p. 17939-17944.

Research output: Contribution to journalArticle

Kolishetti, Nagesh ; Dhar, Shanta ; Valencia, Pedro M. ; Lin, Lucy Q. ; Karnik, Rohit ; Lippard, Stephen J. ; Langer, Robert ; Farokhzad, Omid C. / Engineering of self-assembled nanoparticle platform for precisely controlled combination drug therapy. In: Proceedings of the National Academy of Sciences of the United States of America. 2010 ; Vol. 107, No. 42. pp. 17939-17944.
@article{3399922d0f774db180008c3fdc30078a,
title = "Engineering of self-assembled nanoparticle platform for precisely controlled combination drug therapy",
abstract = "The genomic revolution has identified therapeutic targets for a plethora of diseases, creating a need to develop robust technologies for combination drug therapy. In the present work, wedescribe a self-assembled polymeric nanoparticle (NP) platform to target and control precisely the codelivery of drugs with varying physicochemical properties to cancer cells. As proof of concept, we code-livered cisplatin and docetaxel (Dtxl) to prostate cancer cells with synergistic cytotoxicity. A polylactide (PLA) derivative with pendant hydroxyl groups was prepared and conjugated to a platinum(IV) [Pt(IV)] prodrug, c,t,c-[Pt(NH3)2(O2CCH2CH 2COOH)(OH)Cl2] [PLA-Pt(IV)]. A blend of PLA-Pt(IV) functionalized polymer and carboxyl-terminated poly(D,L-lactic-co-glycolic acid)-block-poly(ethylene glycol) copolymer in the presence or absence of Dtxl, was converted, in microfluidic channels, to NPs with a diameter of ∼100 nm. This process resulted in excellent encapsulation efficiency (EE) and high loading of both hydrophilic platinum prodrug and hydrophobic Dtxl with reproducible EEs and loadings. The surface of the NPs was derivatized with the A10 aptamer, which binds to the prostate-specific membrane antigen (PSMA) on prostate cancer cells. These NPs undergo controlled release of both drugs over a period of 48-72 h. Targeted NPs were internalized by the PSMA-expressing LNCaP cells via endocytosis, and formation of cisplatin 1,2-d(GpG) intrastrand cross-links on nuclear DNA was verified. In vitro toxicities demonstrated superiority of the targeted dual-drug combination NPs over NPs with single drug or nontargeted NPs. This work reveals the potential of a single, programmable nanoparticle to blend and deliver a combination of drugs for cancer treatment.",
keywords = "Chemotherapy, Drug delivery, Polymer-drug conjugate, Targeting, Temporal release",
author = "Nagesh Kolishetti and Shanta Dhar and Valencia, {Pedro M.} and Lin, {Lucy Q.} and Rohit Karnik and Lippard, {Stephen J.} and Robert Langer and Farokhzad, {Omid C.}",
year = "2010",
month = "10",
day = "19",
doi = "10.1073/pnas.1011368107",
language = "English (US)",
volume = "107",
pages = "17939--17944",
journal = "Proceedings of the National Academy of Sciences of the United States of America",
issn = "0027-8424",
number = "42",

}

TY - JOUR

T1 - Engineering of self-assembled nanoparticle platform for precisely controlled combination drug therapy

AU - Kolishetti, Nagesh

AU - Dhar, Shanta

AU - Valencia, Pedro M.

AU - Lin, Lucy Q.

AU - Karnik, Rohit

AU - Lippard, Stephen J.

AU - Langer, Robert

AU - Farokhzad, Omid C.

PY - 2010/10/19

Y1 - 2010/10/19

N2 - The genomic revolution has identified therapeutic targets for a plethora of diseases, creating a need to develop robust technologies for combination drug therapy. In the present work, wedescribe a self-assembled polymeric nanoparticle (NP) platform to target and control precisely the codelivery of drugs with varying physicochemical properties to cancer cells. As proof of concept, we code-livered cisplatin and docetaxel (Dtxl) to prostate cancer cells with synergistic cytotoxicity. A polylactide (PLA) derivative with pendant hydroxyl groups was prepared and conjugated to a platinum(IV) [Pt(IV)] prodrug, c,t,c-[Pt(NH3)2(O2CCH2CH 2COOH)(OH)Cl2] [PLA-Pt(IV)]. A blend of PLA-Pt(IV) functionalized polymer and carboxyl-terminated poly(D,L-lactic-co-glycolic acid)-block-poly(ethylene glycol) copolymer in the presence or absence of Dtxl, was converted, in microfluidic channels, to NPs with a diameter of ∼100 nm. This process resulted in excellent encapsulation efficiency (EE) and high loading of both hydrophilic platinum prodrug and hydrophobic Dtxl with reproducible EEs and loadings. The surface of the NPs was derivatized with the A10 aptamer, which binds to the prostate-specific membrane antigen (PSMA) on prostate cancer cells. These NPs undergo controlled release of both drugs over a period of 48-72 h. Targeted NPs were internalized by the PSMA-expressing LNCaP cells via endocytosis, and formation of cisplatin 1,2-d(GpG) intrastrand cross-links on nuclear DNA was verified. In vitro toxicities demonstrated superiority of the targeted dual-drug combination NPs over NPs with single drug or nontargeted NPs. This work reveals the potential of a single, programmable nanoparticle to blend and deliver a combination of drugs for cancer treatment.

AB - The genomic revolution has identified therapeutic targets for a plethora of diseases, creating a need to develop robust technologies for combination drug therapy. In the present work, wedescribe a self-assembled polymeric nanoparticle (NP) platform to target and control precisely the codelivery of drugs with varying physicochemical properties to cancer cells. As proof of concept, we code-livered cisplatin and docetaxel (Dtxl) to prostate cancer cells with synergistic cytotoxicity. A polylactide (PLA) derivative with pendant hydroxyl groups was prepared and conjugated to a platinum(IV) [Pt(IV)] prodrug, c,t,c-[Pt(NH3)2(O2CCH2CH 2COOH)(OH)Cl2] [PLA-Pt(IV)]. A blend of PLA-Pt(IV) functionalized polymer and carboxyl-terminated poly(D,L-lactic-co-glycolic acid)-block-poly(ethylene glycol) copolymer in the presence or absence of Dtxl, was converted, in microfluidic channels, to NPs with a diameter of ∼100 nm. This process resulted in excellent encapsulation efficiency (EE) and high loading of both hydrophilic platinum prodrug and hydrophobic Dtxl with reproducible EEs and loadings. The surface of the NPs was derivatized with the A10 aptamer, which binds to the prostate-specific membrane antigen (PSMA) on prostate cancer cells. These NPs undergo controlled release of both drugs over a period of 48-72 h. Targeted NPs were internalized by the PSMA-expressing LNCaP cells via endocytosis, and formation of cisplatin 1,2-d(GpG) intrastrand cross-links on nuclear DNA was verified. In vitro toxicities demonstrated superiority of the targeted dual-drug combination NPs over NPs with single drug or nontargeted NPs. This work reveals the potential of a single, programmable nanoparticle to blend and deliver a combination of drugs for cancer treatment.

KW - Chemotherapy

KW - Drug delivery

KW - Polymer-drug conjugate

KW - Targeting

KW - Temporal release

UR - http://www.scopus.com/inward/record.url?scp=78149260773&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78149260773&partnerID=8YFLogxK

U2 - 10.1073/pnas.1011368107

DO - 10.1073/pnas.1011368107

M3 - Article

C2 - 20921363

AN - SCOPUS:78149260773

VL - 107

SP - 17939

EP - 17944

JO - Proceedings of the National Academy of Sciences of the United States of America

JF - Proceedings of the National Academy of Sciences of the United States of America

SN - 0027-8424

IS - 42

ER -